Batch Selection Considerations for RLDs in Bioequivalence Studies

Correct identification of the Reference Listed Drug (RLD) is an important step in planning a bioequivalence (BE) study. However, identifying the appropriate reference product does not necessarily resolve every practical consideration associated with the physical product used in the study.

Commercially available RLDs may exist across different batches, manufacturing periods, expiry windows, and distribution channels.

For development teams, batch selection therefore involves more than product identity alone. Factors such as batch traceability, remaining shelf life, storage history, and availability may influence study planning and the documentation supporting the comparator used in a BE program.

Understanding these considerations helps connect regulatory reference selection with practical study execution.

Why RLD Batch Selection Matters

In a bioequivalence study, the RLD serves as the physical comparator against which the test product is evaluated.

Pharmacokinetic parameters such as AUC and Cmax are generated using the products administered during the study. The characteristics and integrity of the physical RLD supplied for study use therefore form part of the overall study context.

Commercial pharmaceutical products are manufactured in batches, and some degree of batch-to-batch variability may occur within established product specifications.

This does not mean that one commercial batch should automatically be considered preferable to another. Rather, it means that development teams may need to consider the characteristics and suitability of the available batch in the context of the intended study.

Batch selection is therefore an operational consideration that can support a well-planned BE program.

Confirming the Correct Reference Product

Before evaluating individual batches, the first consideration remains correct identification of the reference product.

For a U.S.-focused ANDA program, development teams typically confirm the relevant reference designation using the applicable FDA resources and current regulatory information. As discussed in our explainer on what an RLD is and why it matters, this identification step anchors every downstream sourcing and documentation decision.

Once the appropriate reference product has been identified, the sourcing process moves from regulatory identification to physical supply. At this stage, teams may need to confirm:

• Product name, strength, and dosage form
• Manufacturer or marketer information
• Market of origin
• Batch or lot number
• Expiry date
• Quantity available

Maintaining alignment between the product identified during development planning and the physical product obtained for study use supports documentation consistency.

Considering Batch-to-Batch Variability

Commercial batches of the same RLD are manufactured to approved specifications, but this does not imply that every measurable characteristic will be identical across all batches.

For certain development activities, teams may evaluate characteristics such as dissolution behavior when planning formulation development or comparative studies.

Where batch variability is relevant to a particular development program, the appropriate approach depends on the study objective, product characteristics, available data, and applicable regulatory expectations.

It is therefore important to avoid treating batch selection as a universal formula.

The significance of any observed batch-to-batch differences should be interpreted within the broader development and regulatory context rather than assuming that variation alone determines the suitability of a batch.

Expiry Window and Study Timelines

Remaining shelf life is another practical consideration when sourcing an RLD for BE studies.

A batch may be commercially available and correctly identified but have an expiry date that does not align comfortably with the planned study timeline.

Development teams may need sufficient time for:

• Procurement and international shipment
• Importation and customs procedures
• Receipt and inventory processing
• Study preparation
• Study execution
• Related analytical activities

A limited expiry window can reduce operational flexibility if study schedules change or logistical delays occur.

For this reason, expiry information is commonly considered before procurement rather than after the product has reached the study site.

The appropriate remaining shelf life depends on the specific development program and planned use of the product.

Batch Traceability and Documentation

Traceability helps establish the identity and history of the physical RLD supplied for development use.

Depending on the sourcing route and available commercial documentation, relevant records may include information relating to:

• Product identity
• Batch or lot number
• Expiry date
• Quantity supplied
• Source market
• Supply-chain documentation
• Storage and transportation conditions, where applicable

The exact documentation available can vary by product, market, supplier, and distribution pathway.

Accordingly, development teams should establish their documentation requirements before sourcing rather than assume that every commercial batch will be accompanied by the same records.

Clear batch-level documentation can also help maintain consistency between sourcing records, study documentation, and subsequent regulatory submission materials.

Storage and Handling Considerations

Batch suitability does not depend only on the information printed on the package.

The conditions under which the product is stored and transported may also be relevant to maintaining product integrity.

RLDs should be handled in accordance with the applicable labeled storage conditions throughout the supply process.

For products requiring temperature-controlled transportation or storage, additional planning may be necessary to maintain appropriate conditions and supporting records.

Storage and handling considerations become particularly important when an RLD is sourced internationally and passes through multiple stages before reaching the study site.

The objective is to maintain the integrity and traceability of the physical comparator from sourcing through study use.

Single-Batch vs Multi-Batch Requirements

Not every development program has the same RLD quantity or batch requirements.

A study may be conducted using material from a particular batch, while other development activities may involve additional quantities or batches depending on the program design.

Whether multiple RLD batches should be evaluated or sourced is a program-specific decision. Relevant considerations may include:

• Study design
• Product characteristics
• Development objectives
• Quantity requirements
• Batch availability
• Regulatory strategy

Using multiple batches should not automatically be interpreted as a regulatory requirement, nor should using a single batch be treated as universally sufficient.

The appropriate approach depends on the circumstances of the development program and applicable regulatory expectations.

Implications for RLD Sourcing

Batch selection illustrates why RLD sourcing in generic development is not solely an availability exercise.

The question is not simply: Is the RLD available?

Development teams may also need to ask: Which batch is available, what is its remaining shelf life, what documentation can be provided, and does the available supply align with the intended study timeline and use?

Addressing these questions early can provide greater visibility during BE study planning and reduce the operational uncertainty associated with obtaining additional material later in the program.

This is where regulatory identification, study planning, and pharmaceutical sourcing intersect. As covered in our article on how an RLD is used in BE studies vs ANDA filings, the same physical comparator carries different obligations across the development lifecycle.

Key Takeaways

• The physical batch used in a study introduces practical considerations beyond regulatory designation.
• Batch-to-batch variability should be evaluated in the context of the product, study objective, and applicable regulatory expectations.
• Remaining shelf life should be considered against procurement, logistics, and study timelines.
• Batch-level traceability and available documentation support consistency from sourcing through study use.
• Storage and handling should remain aligned with applicable labeled conditions.
• Single-batch or multi-batch strategies depend on the specific development program rather than a universal rule.

Selecting an RLD batch is therefore not simply a procurement decision. It is an operational component of bioequivalence planning that connects the designated regulatory reference with the physical product ultimately used to generate study data.